REGN4461
Phase 2Small molecule
RegeneronREGN4461 is one of 5 small molecule programs targeting Familial Partial Lipodystrophy. It is currently in Phase 2.
1
Indications
3
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Familial Partial Lipodystrophy
#DrugCompanyPhaseTrials
1Ocaliva
IIntercept Pharmaceuticals
Approved
Volanesorsen
AAkcea Therapeutics
Phase 3
AKCEA-ANGPTL3-Lrx
AAkcea Therapeutics
Phase 2
Myalept
Chiesi Farmaceutici S.p.A.Preclinical
REGN4461
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
ESS1 trial
Familial Partial Lipodystrophy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for REGN4461. EMBL-EBI & Wellcome Sanger Institute.
- [4]